Notice: This company has been marked as potentially delisted and may not be actively trading. Deciphera Pharmaceuticals (DCPH) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends Deciphera Pharmaceuticals (NASDAQ:DCPH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.67%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$58,733.73 Get DCPH Insider Trade Alerts Want to know when executives and insiders are buying or selling Deciphera Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DCPH Insider Buying and Selling by Quarter Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Deciphera Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/16/2024Jama PitmanSVPSell1,624$14.47$23,499.28 1/16/2024Matthew L ShermanEVPSell2,435$14.47$35,234.45 (Data available from 1/1/2013 forward) DCPH Insider Trading Activity - Frequently Asked Questions Who is on Deciphera Pharmaceuticals's Insider Roster? The list of insiders at Deciphera Pharmaceuticals includes Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, Matthew L Sherman, Steven L Hoerter, and Thomas Patrick Kelly. Learn more on insiders at DCPH. What percentage of Deciphera Pharmaceuticals stock is owned by insiders? 4.67% of Deciphera Pharmaceuticals stock is owned by insiders. Learn more on DCPH's insider holdings. Which Deciphera Pharmaceuticals insiders have been buying company stock? The following insiders have purchased DCPH shares in the last 24 months: Brightstar Associates Llc ($29,999,988.00), Dennis Leo Walsh ($152,460.00), and Franklin Stuart Friedman ($138,800.00). How much insider buying is happening at Deciphera Pharmaceuticals? Insiders have purchased a total of 1,687,666 DCPH shares in the last 24 months for a total of $30,291,248.00 bought. Which Deciphera Pharmaceuticals insiders have been selling company stock? The following insiders have sold DCPH shares in the last 24 months: Daniel C Martin ($17,500.90), Daniel Lee Flynn ($51,039.72), Jama Pitman ($58,238.62), Matthew L Sherman ($139,400.31), Steven L Hoerter ($259,307.46), and Thomas Patrick Kelly ($48,525.32). How much insider selling is happening at Deciphera Pharmaceuticals? Insiders have sold a total of 50,953 Deciphera Pharmaceuticals shares in the last 24 months for a total of $690,787.33 sold. More Insider Trading Tools from MarketBeat Related Companies AGIO Insider Trading SNDX Insider Trading XNCR Insider Trading MCRB Insider Trading ROIV Insider Trading RVMD Insider Trading ITCI Insider Trading VKTX Insider Trading LNTH Insider Trading ELAN Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (NASDAQ:DCPH) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Deciphera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
